When was EsoBiotec founded?

EsoBiotec was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is EsoBiotec located?

EsoBiotec is headquartered in Mont-Saint-Guibert, Belgium.

How many employees does EsoBiotec have?

As of Jul 31, 2026, the latest employee count at EsoBiotec is 6.

Is EsoBiotec a funded company?

EsoBiotec is a funded company, having raised a total of $2.15M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2021.

When was the latest funding round of EsoBiotec?

EsoBiotec's latest funding was a $***** Series A round on Dec 11, 2023, with participation from 1 investor.

Where does EsoBiotec rank among its competitors?

EsoBiotec ranks 568th amongst 3471 active competitors, of which 1188 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of EsoBiotec?

EsoBiotec's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

EsoBiotec - 2026 Company Profile, Funding, Competitors & Financials

Q: Is EsoBiotec an acquired company?

EsoBiotec got acquired by AstraZeneca on Mar 17, 2025.

EsoBiotec is an acquired company based in Mont-Saint-Guibert (Belgium), founded in 2020. It operates as a Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.. EsoBiotec has raised $2.15M in funding from investors like Thuja Capital, Sambrinvest and UCB Ventures. The company has 3471 active competitors, including 1188 funded and 808 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

{}

Key Metrics

Founded Year

2020

Location

Mont-Saint-Guibert, Belgium

Stage

Acquired

Total Funding

$2.15M in 2 rounds

Latest Funding Round

Series A, Dec 11, 2023, $*****

Investors

Thuja Capital & 5 more

Ranked

568^th among 3471 active competitors

Employee Count

6 as on Jul 31, 2026

Similar Companies

BeiGene & 935 more

Exit Details

Acquired by AstraZeneca (Mar 17, 2025)

View EsoBiotec's full profile

EsoBiotec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EsoBiotec CIN: 0756.885.159 , Belgium, Active	Oct 21, 2020	-	8 (As on Dec 31, 2022)	-

EsoBiotec got acquired by AstraZeneca on Mar 17, 2025 at an acquisition amount of $*****.

Click here to take a look at EsoBiotec's acquisition in detail

EsoBiotec has raised a total funding of $2.15M over 2 rounds. Its first funding round was on 2021. Its latest funding round was a Series A round on Dec 11, 2023 for $*****. 1 investor participated in its latest round. EsoBiotec has 6 institutional investors.

Here is the list of recent funding rounds of EsoBiotec:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 11, 2023	8897054	Series A	4553731	2747584	1380731	1059564
2021	3847	Seed	5331	3478	UCB Ventures & 3 more	5352

Access funding benchmarks and valuations. Sign up today!

View details of EsoBiotec's funding rounds and investors

EsoBiotec's employee count trend

EsoBiotec has 6 employees as of Jul 26. Here is EsoBiotec's employee count trend over the years:

Uncover EsoBiotec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EsoBiotec include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of EsoBiotec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
568th	EsoBiotec 2020, Mont-Saint-Guibert (Belgium), Acquired	Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.	$2.15M	Thuja Capital, UCB Ventures & 4 others	52/100